XellSmart is a technology company.
XellSmart has raised $26.0M across 2 funding rounds.
XellSmart has raised $26.0M in total across 2 funding rounds.
XellSmart has raised $26.0M in total across 2 funding rounds.
XellSmart's investors include Qiming Venture Partners.
XellSmart Biomedical is a biotechnology company founded in 2021 and headquartered in Suzhou/Shanghai, China, specializing in clinical-grade, off-the-shelf, allogeneic iPSC-derived cell therapies for central nervous system (CNS) diseases with unmet medical needs, such as Parkinson's disease, ALS, spinal cord injury (SCI), and glioblastoma.[1][2][3][4] It serves patients lacking effective treatments by developing regenerative neural cell therapies, supported by proprietary platforms, a 5,000+ m² R&D and GMP manufacturing facility, and seven IND approvals from China's NMPA and U.S. FDA for Phase I/registrational trials.[1][2][3][4] The company has demonstrated strong growth momentum, including FDA clearance for three Phase I INDs in 2025 targeting Parkinson's, SCI, and ALS; initiation of China's first national iPSC therapy trial for Parkinson's in 2024; and multiple GMP-grade clinical batches deployed in ongoing global trials, backed by funding from Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others.[3][4]
XellSmart was founded in 2021 by Xiang Li, who serves as CEO, Chief Scientific Officer, and Founder, amid a push for scalable stem cell solutions for neurodegenerative diseases without clinical treatments.[1][4][5] The idea emerged from over four years of preclinical development focusing on iPSC-derived therapies for CNS conditions like Parkinson's and ALS, leading to rapid milestones such as FDA Orphan Drug Designation for XS228 (ALS) in 2023 and China's first registered iPSC trial for Parkinson's in 2024.[1][4] Early traction included building an "All-In" international team, proprietary industrial platforms, and a comprehensive GMP facility, culminating in 2025 FDA/NMPA approvals for the world's first registrational Phase I trial of allogeneic iPSC-derived neural cells for SCI—affecting over 15 million globally.[3]
XellSmart rides the surging wave of iPSC-derived cell therapy innovation, particularly for CNS regeneration, amid global demand for treatments targeting 15+ million SCI patients and millions more with Parkinson's/ALS where options are limited.[1][3] Timing is ideal post-2020s advances in gene editing and stem cell scalability, fueled by China's biotech incentives and U.S. FDA fast-tracks like orphan status, enabling dual-market progress.[2][4] Market forces favoring it include aging populations driving neurodegenerative demand, falling iPSC production costs, and investor appetite from top VCs, amplifying China's rise as a cell therapy hub.[4] It influences the ecosystem by pioneering "off-the-shelf" allogeneic models, reducing patient-specific hurdles, and setting benchmarks via first-in-world trials that could accelerate industry-wide adoption.[3]
XellSmart is primed for Phase II expansions and potential partnerships, with its 2025 trial approvals signaling near-term data readouts that could validate iPSC efficacy in CNS repair. Trends like AI-optimized cell engineering and global harmonized regulations will accelerate its pipeline, potentially yielding first approvals by 2028-2030. Its influence may evolve from China-centric innovator to global leader, reshaping regenerative medicine for untreatable diseases and delivering hope where none existed—echoing its mission to redefine SCI and neurodegeneration recovery.[3][4]
XellSmart has raised $26.0M across 2 funding rounds. Most recently, it raised $14.0M Series B in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $14.0M Series B | Qiming Venture Partners | |
| Sep 1, 2021 | $12.0M Seed | Qiming Venture Partners |